Shares of DexCom Inc. (NASDAQ:DXCM) rose 7% on Tuesday . The stock traded as high as $86.35 and last traded at $83.68, with a volume of 1,764,711 shares. The stock had previously closed at $78.19.

DXCM has been the subject of several analyst reports. JPMorgan Chase & Co. reiterated a “buy” rating on shares of DexCom in a research note on Monday, June 20th. Deutsche Bank AG lifted their price objective on shares of DexCom from $90.00 to $98.00 and gave the stock a “buy” rating in a research note on Friday. Jefferies Group reiterated a “buy” rating and issued a $98.00 price objective (up previously from $90.00) on shares of DexCom in a research note on Friday. Canaccord Genuity restated a “buy” rating and issued a $95.00 target price on shares of DexCom in a research report on Wednesday, July 13th. Finally, BTIG Research started coverage on shares of DexCom in a research report on Thursday, April 14th. They issued a “buy” rating and a $80.00 target price for the company. Three equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $93.82.

The firm has a 50 day moving average price of $74.99 and a 200-day moving average price of $68.39. The firm’s market cap is $6.97 billion.

DexCom (NASDAQ:DXCM) last issued its earnings results on Wednesday, April 27th. The medical device company reported ($0.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by $0.03. The business had revenue of $116.20 million for the quarter, compared to analysts’ expectations of $110.37 million. The firm’s revenue for the quarter was up 59.6% on a year-over-year basis. During the same period in the previous year, the company earned ($0.17) EPS. On average, equities research analysts predict that DexCom Inc. will post ($0.35) earnings per share for the current fiscal year.

In other news, SVP Jeffrey Moy sold 6,866 shares of the stock in a transaction dated Wednesday, June 8th. The shares were sold at an average price of $71.00, for a total value of $487,486.00. Following the sale, the senior vice president now directly owns 76,333 shares of the company’s stock, valued at $5,419,643. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Barbara Kahn sold 3,000 shares of the stock in a transaction dated Thursday, May 12th. The stock was sold at an average price of $60.72, for a total transaction of $182,160.00. Following the completion of the sale, the director now directly owns 42,804 shares in the company, valued at $2,599,058.88. The disclosure for this sale can be found here.

Other large investors have recently made changes to their positions in the company. Trexquant Investment LP purchased a new stake in shares of DexCom during the fourth quarter worth about $1,515,000. Artemis Investment Management LLP increased its stake in shares of DexCom by 90.9% in the fourth quarter. Artemis Investment Management LLP now owns 19,792 shares of the medical device company’s stock worth $1,620,000 after buying an additional 9,424 shares during the last quarter. I.G. Investment Management LTD. increased its stake in shares of DexCom by 149.7% in the fourth quarter. I.G. Investment Management LTD. now owns 23,852 shares of the medical device company’s stock worth $1,953,000 after buying an additional 14,300 shares during the last quarter. Principal Financial Group Inc. increased its stake in shares of DexCom by 13.2% in the fourth quarter. Principal Financial Group Inc. now owns 79,782 shares of the medical device company’s stock worth $6,534,000 after buying an additional 9,277 shares during the last quarter. Finally, Rhumbline Advisers increased its stake in shares of DexCom by 0.5% in the fourth quarter. Rhumbline Advisers now owns 88,844 shares of the medical device company’s stock worth $7,276,000 after buying an additional 480 shares during the last quarter.

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers for the treatment of people with and without diabetes. Its products include SEVEN PLUS, DexCom G4, DexCom G4 PLATINUM, DexCom Share System and DexCom G5 Mobile.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.